bioquiddity logo link to home page
AUGUST 2015
    BioQuiddity and Lee’s Pharmaceutical Enter Agreement to Jointly Commercialize Two Infusion Pharmaceuticals in China, Taiwan, Hong Kong, and Macau
JULY 2015
    BioQuiddity Appoints
    Daniel Tassé to its Board
    of Directors
MAY 2015
    BioQuiddity Enters Into an Exclusive License and Supply Agreement to Commercialize Two Ready‐to‐Use Infusion Products in the United States
JULY 2014
    Cipla and BioQuiddity announce
    EU Commercial Partnership for OneDose-ReadyfusOR for Post-Surgical Pain Management
DECEMBER 2013
    N. W. (Bill) Jasper Jr. elected to
    Board of Directors

BioQuiddity Enters Into an Exclusive License and Supply Agreement
to Commercialize Two Ready‐to‐Use Infusion Products in the
United States

San Francisco, CA, May 13, 2015
BioQuiddity Incorporated, a specialty pharmaceutical company, today announced the signing of an exclusive license and supply agreement with Sandoz, a division of Novartis, under which Sandoz has the right to market BioQuiddity’s ready‐to‐use ropivacaine and propofol infusion pharmaceutical products in the United States. Under the agreement, BioQuiddity is responsible for obtaining the requisite regulatory approvals and supplying the unit‐dose infusion systems, and Sandoz is responsible for marketing and commercializing the products.

“We are thrilled to collaborate with Sandoz, a proven leader in the healthcare industry. Our ready‐to-use drug delivery platform provides a therapy specific solution that is immediately deployable at the point of care without multiple preparation steps,” said Josh Kriesel, President and CEO of BioQuiddity. “We look forward to rapidly offering a portfolio of innovative cost effective infusion solutions in the United States through this collaboration.”

About BioQuiddity Inc.
BioQuiddity is a privately held specialty pharmaceutical company focused on developing and commercializing ready‐to‐use infusible pharmaceuticals. The Company’s infusion platform addresses some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life. BioQuiddity’s vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via the Company’s proprietary unit‐dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. The Company is ISO13485 certified. West Pharmaceutical Services, an existing strategic partner of BioQuiddity’s, will be assembling the ready‐to‐use infusion systems.

BioQuiddity Contact Information:
Josh Kriesel
President and CEO
415‐336‐6496

Ron Pauli
Chief Financial Officer
415‐889‐7707

Media:
Stephanie Carrington
Integrated Corporate Relations, Inc (ICR)
stephanie.carrington@icrinc.com
646‐277‐1282